Sinopharm vaccine on 900 children aged 3 to 17 effective in reducing infection rate in Abu Dhabi, says study

Sinopharm vaccine on 900 children aged 3 to 17 effective in reducing infection rate in Abu Dhabi, says study
Sinopharm vaccine on 900 children aged 3 to 17 effective in reducing infection rate in Abu Dhabi, says study

Hello and welcome to the details of Sinopharm vaccine on 900 children aged 3 to 17 effective in reducing infection rate in Abu Dhabi, says study and now with the details

Nevin Al Sukari - Abu Dhabi - Gulf Today, Staff Reporter

The Abu Dhabi health body announced that the target has been achieved for the Sinopharm Immune Bridge Study on children aged 3 to 17 years in Abu Dhabi.

The study was conducted under the supervision of the Ministry of Health and Prevention (MoHAP).

The study followed the effectiveness of the COVID-19 vaccine in reducing the infection rate and the severity of symptoms in the target population.

The study examined 900 children of different nationalities who met the criteria for participating in the study. It was done with the full consent of the parents, and all young volunteers are closely monitored and cared for at every step of the whole process.

All applicable medical protocols are implemented in accordance with the highest international standards and practices.

Once these measures are in place, preliminary studies will be announced to help develop plans for students to return to school in a safe and healthy manner.

The registration for this study was successful because we recruited the required number of children in a short period of time.

In addition, the health authorities praised the significant role played by the Abu Dhabi Health Services Company (SEHA) in performing procedures and manage medical agreements to ensure that the goals of this study are achieved.  

The United Arab Emirates is the first country in the Middle East and North Africa to conduct a vaccine effectiveness study for this age group.

Other vaccine-producing countries, such as China, the United States, the United Kingdom, and India, have conducted similar clinical trials in recent months.

Dr. Nawal Al Kaabi, Principal Investigator for Phase III Trials COVID-19 vaccine said that the enrollment registration for this study has been successful as we have attracted the desired number of children within a short period of time.  

I would like to thank everyone who took the initiative to register and participate in this study to support the country’s efforts to combat the COVID-19 pandemic.

These were the details of the news Sinopharm vaccine on 900 children aged 3 to 17 effective in reducing infection rate in Abu Dhabi, says study for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Gulf Today and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

NEXT Etisalat gives schools award-winning books